Our previous study reported that low presence of CD86+ M1 TAMs and high presence of CD206+ M2 TAMs were significantly correlated with aggressive tumor phenotypes and worse prognosis in HCC patients (Dong et al., 2016). This evidence concerns the gene CD86 and neoplasm.